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Abstract
Background: Gene therapy in the hematopoietic system remains promising, though certain aspects of vector
design, such as transcriptional control elements, continue to be studied. Our group has developed a retroviral
vector where transgene expression is controlled by p53 with the intention of harnessing the dynamic and
inducible nature of this tumor suppressor and transcription factor. We present here a test of in vivo expression
provided by the p53-responsive vector, pCLPG. For this, we used a model of serial transplantation of transduced
bone marrow cells.
Results: We observed, by flow cytometry, that the eGFP transgene was expressed at higher levels when the
pCLPG vector was used as compared to the parental pCL retrovirus, where expression is directed by the native
MoMLV LTR. Expression from the pCLPG vector was longer lasting, but did decay along with each sequential
transplant. The detection of eGFP-positive cells containing either vector was successful only in the bone marrow
compartment and was not observed in peripheral blood, spleen or thymus.
Conclusions: These findings indicate that the p53-responsive pCLPG retrovirus did offer expression in vivo and at a
level that surpassed the non-modified, parental pCL vector. Our results indicate that the pCLPG platform may
provide some advantages when applied in the hematopoietic system.
Background
The merits and shortcomings related to the use of retro-
viral vectors for laboratory and clinical gene transfer
have been intensely studied. Vectors derived from the
Moloney Murine Leukemia Virus (MoMLV) hold an
important, historical place in the development of clinical
gene therapy. These vectors are relatively easy to pro-
duce and manipulate, are quite malleable and are extre-
mely efficient, especially when applied ex vivo [1].
However, they have been associated with severe adverse
events in clinical trials for the treatment of X-SCID [2]
and the silencing of retroviral expression in vivo has
been observed [3,4].
The MoMLV long terminal repeat (LTR) can be
employed to drive transgene expression and is a robust
promoter, especially in cultured cells. However, the viral
promoter tends to suffer methylation and consequently
is silenced, particularly when transduced hematopoietic
stem cells (HSC) are transplanted in recipients [3,4].
Silencing of the MoMLV LTR can be avoided if the
transgene contributes to positive selection of those cells
that maintain viral expression [5]. In the X-SCID trials,
the transgenes provided an advantage related to trans-
duction of growth-promoting signals [6,7]. Many treat-
ment protocols require the transfer of a therapeutic
gene that does not contribute to positive selection. In
this situation, prolonged vector expression may require
modification of the LTR itself in order to promote tran-
scription and avoid the cellular mechanisms that cause
methylation [4].
In our previous studies, we altered the LTR of a typi-
cal MoMLV-derived vector such that transgene expres-
sion is driven by p53. This vector, called pCLPG, was
shown to express reporter genes at levels superior to the
parental vector, pCL, which utilizes the native MoMLV
LTR to drive transgene expression [8]. We have also
inserted the wild-type p53 cDNA under the control of
this p53-responsive promoter and showed that an auto-
regulatory, positive feedback mechanism was established,
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resulting in improved expression of p53 as well as
greater tumor cell inhibition when tested in tissue cul-
ture [9]. However, until now, we had not tested the
pCLPG vector in a model that would test its potential
for application in vivo.
Since retroviral vectors are best suited for ex vivo gene
transfer and one of their typical uses in clinical trials has
been in the hematopoietic system, we wished to test the
pCLPG vector in such a model. Mouse models of serial
transplantation of transduced bone marrow cells have
often been used for this purpose since it places pressure
on the stem cells to self renew and repopulate the
hematopoietic system of the irradiated recipient [10,11].
In a relatively short period of time, this model can pro-
vide rigorous testing of the sustainability of vector
expression. In addition, such models can also reveal
potential adverse events related to the presence of the
vector and transgene [12].
We show here that the pCLPG vector does indeed
support expression in vivo. At least in the bone marrow
compartment, expression from the pCLPG vector was
sustained at a higher level and for a longer period of
time than was seen for pCL. The use of a p53-respon-
sive vector may prove to be an interesting option for
gene transfer in the hematopoietic system.
Results
p53-responsiveness of the pCLPG vector in the context of
a hematopoietic cell
A tissue culture assay was performed in order to deter-
mine if the expected p53-dependence of the pCLPG
vector would be preserved in hematopoietic cells. For
this, the pCLeGFP or pCLPGeGFP vectors (Figure 1A)
were used to transduce K562 cells (human chronic mye-
logenous leukemia, p53-null) which were then selected
for G418 resistance. The p53(223) temperature sensitive
mutant [13] was introduced by a second round of retro-
viral transduction followed by selection with puromycin.
The different cell types were then cultivated at either
32°C (permitting transactivational functions of the p53
mutant) or at 37°C (restricting p53 activity due to the
mutant conformation of the protein). As shown in Fig-
ure 1B, the activation of the pCLPGeGFP vector was
evident only when cells harboring this vector plus the
p53(223) mutant were cultivated at 32°C. In contrast,
the pCLeGFP vector was not affected by p53 status or
temperature. This assay shows that, as expected, the
pCLPG vector can be activated specifically by p53 in a
hematopoietic cell.
Serial transplantation of transduced bone marrow
In order to assess the expression of the p53-responsive
pCLPG vector in vivo, a model of serial bone marrow
transplantation was used. For this procedure, as shown
in Figure 2, total bone marrow cells (BMC) were col-
lected from male donor mice previously injected with 5-
fluorouracil (5 FU). These cells were either mock trans-
duced or transduced with the retroviral vectors
pCLeGFP or pCLPGeGFP. These cells were then trans-
planted in isogenic female mice. The primary transplant
recipients were maintained for two months before divid-
ing the animals into sub-groups for analysis, continued
observation or recovery of BMC for use in serial trans-
plantation. In addition, male mice age-matched with the
donor mice were maintained as controls for hematologic
exams.
The transduction of BMC with either the pCLeGFP or
pCLPGeGFP vectors resulted in approximately 8 and
10% eGFP positive cells, respectively, as determined by
flow cytometry (Figure 3). The intensity of eGFP fluor-
escence in cells transduced with either vector was quite
similar, indicating that the expression from the p53-
responsive pCLPG vector was as robust as the parental
pCL virus. These cells were used to transplant the pri-
mary recipients, as described in Table 1, who were then
used as donors in subsequent transplants.
Evaluation of eGFP expression in cells recovered from
transplant recipients
Analysis of eGFP expression in BMC, peripheral blood,
spleen and thymus was performed after short or long
term observation. eGFP-positive cells were observed
only in BMC recovered from the transplant recipients,
but not in the other tissues analyzed. As shown in Fig-
ure 4, the pCLPG vector provided superior expression
of the transgene as compared to the parental pCL vec-
tor, especially among the primary and secondary recipi-
ents observed 2 months post-transplant. Expression
from the pCLPG vector did decay by the tertiary trans-
plant and in the animals maintained for long term
observation. Though the level of pCLPG expression was
significantly greater than that seen with the parental
pCL vector, the difference was quite small, especially at
the long term observation point.
Proviral copy number was assessed by real time PCR
detection of vector sequences and comparing this level
to a standard curve. As shown in Table 2, the number
of provirus detected in the genomic DNA (gDNA) iso-
lated from the BMC recovered from the transplanted
animals ranged from 0.02-0.04 for the pCLeGFP group
and 0.03-0.07 for the pCLPGeGFP group. We interpret
this result as an indication that vector silencing was not
observed in the BMC since the number of eGFP-positive
cells closely matched the proportion of cells carrying
provirus. However, the level of provirus was below the
limit of quantification permitted by this assay when per-
ipheral blood, spleen and thymus were analyzed (data
not shown).
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Figure 1 p53-dependent expression from pCLPGeGFP revealed in a hematopoietic cell line. (A) Schematic representation of the parental,
non-modified gamma retroviral vector, pCLeGFP, which utilizes the native LTR to drive transgene expression. For pCLPGeGFP, the LTR was
modified by the removal of the enhancer region and insertion of a p53-responsive element, as described previously [8,9]. (B) K562 cells were
used to test expression of the pCLeGFP and pCLPGeGFP vectors in response to p53 activity (intensity of eGFP; au, arbitrary units). The data
represent the mean and standard deviation of duplicate samples from 3 independent experiments.
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Evaluation of chimerism was also performed by real
time PCR detection of the Y chromosome in BMC
recovered from the transplant recipients. In all cases,
greater than 95% of the cells contained the Y chromo-
some, indicating that repopulation of the hematopoietic
system in the female recipient mice was due to the
implantation of the male BMC.
Hematologic exams were performed at the time of
sacrifice of the transplanted animals. After short term
observation, the only change that was noted was micro-
cytic anemia (Table 3). This was present in the mock
transduction as well as pCLeGFP and pCLPGeGFP
groups, indicating that the presence of the vector was
not responsible for this change. We show here only the
tertiary transplant group since we would expect altera-
tions, if they should occur, to be exaggerated in this
group. The hematologic exams from the tertiary trans-
plant recipients closely matched those of the other
groups (Additional File 1). After long term observation,
the apparent anemia was no longer present as evidenced
by mean hemoglobin and mean corpuscular hemoglobin
concentrations having returned to normal (Table 4 and
Additional File 2).
In vivo treatment with 5-azacytidine corroborates lack of
methylation in BMC
Animals from the long term observation groups were
treated with 5-azacytidine (5-aza) in vivo, 24-hours prior
to sacrifice. By flow cytometric evaluation of eGFP activ-
ity, we noted that little or no change was present in cells
recovered from the bone marrow compartment, though
peripheral blood, spleen and thymus each revealed an
extremely modest increase in the number of eGFP-posi-
tive cells detected after 5-aza treatment (data not
shown).
As an additional measure of the impact of 5-aza,
quantification of proviral sequences by real time PCR
was performed in samples recovered from both treated
and control animals. When corrected for amplification
of a genomic segment of the b-Actin gene, no altera-
tion in provirus was observed (data not shown). Taken
together, the lack of response to in vivo treatment with
Figure 2 Experimental design of serial transplantation. Three groups of animals were treated with this procedure (mock-transduced BMC;
animals receiving pCLeGFP-transduced BMC; animals receiving BMC transduced with pCLPGeGFP). Analysis included detection of eGFP by flow
cytometry, hematologic exams, collection of gDNA and posterior determination of provirus copy number and chimerism.
Table 1 Summary of transplant procedure utilized
1° Transplant 2° Transplant 3° Transplant
Survival of non-transplanted control animals 18-21d
(n = 3)
18-22d
(n = 3)
17-21d
(n = 3)
Donor animals
(male, C57BL/6)
n = 17 NA NA
BMC collected 1-1.5 × 107 total cells/donor 1-1.5 × 107 total cells/donor 1-1.5 × 107 total cells/donor
Total number of recpients (female, C57BL/6) n = 18 n = 17 n = 12
Donor animals used for serial transplant n = 6a n = 5b NA
Short term maintenance of transplant recipients 64 d
(n = 6)
59 d
(n = 6)
62 d
(n = 6)
Long term maintenance of transplant recipients 10 m
(n = 6)c
8 m
(n = 6)c
6 m
(n = 6)c
a, Primary transplant recipients that were used as donors in the secondary transplant
b, Secondary transplant recipients that were used as donors in the tertiary transplant
c, Three animals in each long term group received 1 mg/kg 5-aza 24h prior to sacrifice
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5-aza may suggest that silencing of vector expression
was not a significant issue in these assays.
Discussion
Using a model of serial bone marrow transplantation,
we have shown that expression from the p53-dependent
pCLPG retroviral vector was superior to that of the par-
ental, constitutive pCL vector. For both vectors, expres-
sion was limited to the bone marrow compartment and
was not detected in peripheral blood, spleen or thymus.
Since the number of eGFP-positive BMC was closely
correlated with the provirus copy number detected in
these cells, these results suggest that no vector silencing
was observed in this compartment. In addition, in vivo
treatment with 5-aza did not increase the number of
eGFP-positive cells in the bone marrow compartment,
corroborating the idea that silencing was not an issue in
these cells.
Evaluation of provirus copy number present in the
BMC recovered after the short term observation of pri-
mary transplant recipient mice suggests that 7/100 or 4/
100 cells contained a single pCLPGeGFP or pCLeGFP
provirus, respectively. We presume that only a single
copy, on average, would have integrated in these cells
due to the low overall transduction efficiency. Reports
in the literature indicate that multiple copies would be
present only at transduction efficiencies above 30% [14].
Moreover, eGFP expression in the BMC of the recipient
mice was positive in approximately 7/100 or 4/100 cells
recovered from the pCLPGeGFP or pCLeGFP transplant
groups, respectively. This correlation between provirus
copy number and observation of transgene expression
suggests that vector silencing was not a problem, at
least in BMC. The lack of vector expression in periph-
eral blood, thymus and spleen is also consistent with the
difficulty in quantifying provirus in these tissues.
For our experiments, we chose to transduce total
BMC since this procedure has long been, and continues
to be, widely used. For example, classic studies from the
group of Donald Kohn have shown methylation of the
native MoMLV LTR, but reliable expression from a
modified vector when total BMC was transduced and
followed by serial transplantation [3,4,10,11,15]. The
work of Andersson et al, 2003, also used total BMC for
transduction with a GFP-expressing retrovirus which,
upon transplantation, prevented rejection of eGFP-trans-
genic skin grafts [16]. In 2006, the group of Brian Sor-
rentino also used the tansduction of total BMC
recovered from X-SCID mice followed by transplanta-
tion to reveal the phenotypic tendency of these cells to
transform [17].
The ex vivo transduction procedure used here resulted
in a relatively low level of gene transfer in bone marrow
cells. A recent report indicates that retrovirus produced
in NIH3T3-derived packaging cells offers some advan-
tages for the transduction of hematopoietic stem cells,
namely the production of fibronectin, yet 293T cells
barely produce this protein [18]. The presence of fibro-
nectin in the virus preparation facilitates the preloading
of viral particles onto the culture dish. The use of Retro-
nection (recombinant fibronectin fragment CH-296),
intended to provide a substrate onto which the viral
particles can be seeded, was not advantageous when
virus was produced in 293T [18]. In addition, virus
pseudotyped with the VSVg envelope is not efficiently
preloaded on Retronectin [19]. Both of these findings
are consistent with our previous study where virus was
produced in 293T cells with either amphotropic or
VSVg envelopes and transduction was performed either
with or without Retronectin, resulting in little change to
transduction efficiency in BMC or K562 [PF and BES,
unpublished data]. The use of 293T cells for virus
Figure 3 Observation of eGFP expression in donor BMC. Total BMC were collected from male donor mice, stimulated with cytokines and
either mock transduced or transduced with pCLeGFP or pCLPGeGFP in the presence of Retronectin and analyzed by flow cytometry for eGFP
expression 48-hours later (percentage of eGFP-positive cells and intensity of eGFP; au, arbitrary units).
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Figure 4 Analysis of eGFP expression by flow cytometry in cells recovered from transplant recipients. Short term (two months after
transplant) or long term (6 to 10 months after transplant) observation cohorts were sacrificed after primar, secondary or tertiary transplantation
(1°, 2° or 3°) and recovered cells were analyzed by flow cytometry for eGFP expression (percentage of eGFP-positive cells and intensity of eGFP;
au, arbitrary units). Bars represent the mean and standard deviation among samples from the same cohort (please see Table 1 for the number of
animals in each group). For statistical analysis, the Student’s t-test (paired, 1-tailed; *, p < 0.0005; **, p < 0.005; #, p < 0.05) was performed using
Excel, comparing pCLeGFP and pCLPGeGFP cohorts for each condition.
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production may be partly to blame for the low transduc-
tion efficiency observed in our studies.
As revealed in the short term observation groups of
our experiments, the expression of the p53-responsive
pCLPG vector was maintained longer and at a higher
level than was seen for the parental pCL vector, at least
as revealed in the primary and secondary transplant
recipients. Loss of pCLPG expression in BMC does not
seem to be related to vector silencing, but instead to the
gradual loss of transduced cells during successive trans-
plant procedures. In contrast, viral expression in the
long term observation groups was quite similar between
the two vectors. This implies that the pCLPG, without
additional activation of p53, is superior to the pCL
vector, at least in BMC and during the first months fol-
lowing transplant.
Taken together, the use of total BMC and the low
trasduction efficiency may have contributed to the low
level of viral marking in peripheral blood, spleen and
thymus. Since the true hematopoieitic stem cells repre-
sent only a small portion of BMC, the odds are low that
these cells were transduced in our experiments. Though
we did not characterize the transduced BMC prior to
transplantation, it is possible that those cells which were
transduced were of a more committed phenotype. This
situation would also be consistent with the loss of viral
marking upon successive transplants since the trans-
duced cells would have a finite life span and would be
expected to die over time.
Vector silencing by methylation is a common problem
in retroviral vectors that use the non-modified MoMLV
LTR to drive transgene expression. However, the
pCLPG vector was modified in the LTR, prompting us
to evaluate its performance in this serial transplantation
model. If silencing by methylation had occurred, then
treatment with 5-azacytidine should lead to an increase
in eGFP-positive cells. Treatment with 5-aza did not
result in the alteration of eGFP-positive cells in BMC.
Therefore, direct assessment of methylation in the retro-
viral LTR by methylation-specific sequencing was not
performed in this study.
Although further testing is still required, we propose
that a p53-responsive vector may be beneficial for gene
therapy applications in the hematologic system. For exam-
ple, the expression of the splice-corrected MDR1 cDNA
by pCLPG in HSC could be induced by chemotherapeutic
drugs that activate p53, such as doxorubicin. In this sce-
nario, the chemotherapy drug should not only kill tumor
cells, but also induce the expression of MDR1 from the
pCLPG vector and thus protect the hematopoietic system
Table 2 Determination of provirus copy number and
chimerism by real-time PCR
Short term
Chimerisma Copy number (BMC)b
Non-transduced ND NA
pCLeGFP
1° >95% 0.03-0.04
2° >95% 0.02-0.03
3° >95% 0.02-0.03
pCLPGeGFP
1° >95% 0.06-0.07
2° >95% 0.04
3° >95% 0.03
a, Chimerism determined using gDNA isolated from BMC recovered from
transplant recipients where amplification of a Y-chromosome sequence was
compared to a standard curve
b, copy number was determined by amplifying a viral sequence and
comparing this to a standard curve. Note that provirus was not quantifiable
by this assay in peripheral blood, spleen or thymus.
ND, not determined
NA, not applicable
Table 3 Representative hematologic analyses of transplant groups after short term observation
Male age-matched mice Non-transduced
3° transplant
Short term
pCLeGFP
3° transplant
Short term
pCLPGeGFP
3° transplant
Short term
RBC× 106/mm3 7.88 ± 0.10 8.51 ± 0.46 8.41 ± 0.42 8.51 ± 0.40
Hematocrit % 38.8 ± 1.16 46 ± 4.50 48 ± 4.0 46 ± 4.60
Hemoglobin g/dl 12.92 ± 0.34 11.92 ± 0.19 12.91 ± 0.34 12.92 ± 0.39
Mean globular volume % (MGV) 56.93 ± 3.02 60.83 ± 2.10 62.55 ± 3.50 60.64 ± 3.51
Mean hemoglobin concentration fl 30.21 ± 0.83 18.70 ± 3.68 19.92 ± 0.75 19.70 ± 0.61
Mean corpuscular hemoglobin concentration % (MCHC) 21.60 ± 1.80 36.16 ± 4.75 36.86 ± 4.90 37.16 ± 0.15
WBC× 103/mm3 6.48 ± 0.14 4.27 ± 0.79 4.52 ± 0.98 4.27 ± 0.30
Eosinophils % 01 ± 0.75 02 ± 0.51 2.4 ± 0.75 02 ± 0.75
Monocytes % 02 ± 0.51 02 ± 1.36 03 ± 1.65 03 ± 0.89
Lymphocytes% 68.6 ± 2.68 67.6 ± 2.31 72.6 ± 0.98 77.5 ± 1.72
Neutrophils % 43.4 ± 2.09 28.75 ± 1.96 27.75 ± 2.25 29 ± 2.29
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from the drug’s effect, yet removal of the drug would
result in the reduction in vector expression.
The insertion of the retroviral vector may induce the
unwanted expression of a neighboring oncogene. In the
case of pCLPG, the enhancer is dependent on p53 activ-
ity, implying that induction of the oncogene and p53
would be juxtaposed and may lead to elimination of
these cells through apoptosis coordinated by p53. Lenti-
viral vectors are thought to be a safer alternative to
gamma retroviral vectors [20]. The concept of p53-dri-
ven viral expression could be transferred to lentiviral
vectors, maintaining the dynamic control over transgene
expression and, possibly, gaining the relative safety of a
vector that tends to integrate at a distance from gene
promoters [21].
As revealed in the short term observation of primary
and secondary transplant recipients, the pCLPG vector
provided superior expression as compared to the paren-
tal vector. This indicates that gene transfer vectors that
utilize p53 to drive transgene expression may be of
interest for application in the hematopoietic system.
Methods
Viral vectors
The pCLeGFP and pCLPGeGFP vectors have been
described previously [9,22]. It should be noted that in
our previous work, the pCLPG vector was referred to as
pCLPG-ΔU3, and has been re-named for simplicity.
Virus production
To produce virus-containing supernatant, the indicated
viral vectors were co-transfected in the 293T cells as
described [23], except using pCMV-gag-pol and pCMV-
VSVg packaging vectors (kindly provided by Richard Mul-
ligan, Harvard Medical School, Boston, MA, USA and Jane
Burns, University of California, San Diego, USA,
respectively). After 24 hours of incubation, the virus-con-
taining supernatant was collected, centrifuged for 5 min-
utes, 1000 ×g, then the supernatant removed and
concentrated by ultracentrifugation (100,000 ×g, 120 min).
The viral pellet was resuspended by overnight incubation
in Hank’s Balanced Salt then aliquoted and stored at -70°C.
Titration of virus preparations
Titration was performed by transducing NIH3T3 cells
then counting eGFP-positive cells by flow cytometry.
This protocol has been described previously [22]. Typi-
cal titers were in the range of 1-3 × 106 green fluores-
cence units (gfu)/ml before ultracentrifugation and 2 ×
108 gfu/ml after.
Temperature sensitive p53 assay
K562 cells were transduced with pCLeGFP or
pCLPGeGFP at an MOI of 1 then selected for G418
resistance. These cells were then transduced with a sec-
ond retroviral vector, pLPCp53(223) (kindly provided by
Andrei Gudkov, Lerner Research Institute, Cleveland,
OH) which encodes the human p53 mutant P223L as
well as the puromycin resistance gene. The cells were
treated with puromycin, 1 μg/ml, until control cells had
died. Approximately 1 × 106 cells of each type were pla-
ted in duplicate 6-well dishes. One dish was maintained
at 37°C and the other at 32°C for 24 hours before har-
vesting the cells and analysis by flow cytometry of the
percentage of eGFP-positive cells as well as the intensity
of eGFP activity, as determined by the cytometry
software.
Collection and cultivation of bone marrow cells (BMC)
Animal handling procedures and experimental design
was approved by institutional ethics committees (Biome-
dical Sciences Institute, protocol 097/04, as well as the
Table 4 Representative hematologic analyses of transplant groups after long term observation
Male age-matched mice Non-transduced
3° transplant
Long term
pCLeGFP
3° transplant
Long term
pCLPGeGFP
3° transplant
Long term
RBC× 106/mm3 5.87 ± 0.034 6.31 ± 0.099 5.93 ± 0.39 6.18 ± 0.31
Hematocrit % 37.5 ± 1.29 35.6 ± 1.14 40.8 ± 2.39 42 ± 2.45
Hemoglobin g/dl 12.67 ± 0.027 11.57 ± 0.39 11.65 ± 0.43 11.77 ± 0.38
Mean globular volume % (MGV) 63.77 ± 0.099 65.066 ± .011 67.49 ± 0.47 67.92 ± 0.11
Mean hemoglobin concentration fl 21.25 ± 0.036 21.69 ± 0.23 22.64 ± 0.36 22.99 ± 0.15
Mean corpuscular hemoglobin concentration % (MCHC) 30.5 ± 2.38 32.49 ± 0.32 31.71 ± 0.45 32.12 ± 0.29
WBC× 103/mm3 4.7 ± 0.059 4.62 ± .017 3.73 ± 0.26 4.024 ± 0.074
Eosinophils % 2 ± 0.82 1.4 ± 0.89 0.4 ± 0.55 0.4 ± 0.89
Monocytes % 3.75 ± 0.5 1.4 ± 0.54 1.2 ± 0.45 1.6 ± 0.55
Lymphocytes% 63.94 ± 0.077 68.45 ± 0.32 66.082 ± 0.46 65.92 ± 0.43
Neutrophils % 48 ± 1.14 44.76 ± 1.43 42.43 ± 0.51 42.85 ± 0.71
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School of Medicine, USP, research protocol SDS 2832/
06/077). Young adult (approximately 90 days old), male
C57BL/6 mice (obtained from the Centro de Bioterismo,
FM-USP) were injected i.p. with 5-fluorouracil (5-FU),
150 mg/kg, and maintained for 7 days. The mice were
then sacrificed and their tibias and femurs isolated.
BMC were flushed from the bones upon washing with
medium (Iscove’s Modified Eagle Medium, IMDM, con-
taining 15% fetal calf serum, FCS, Hyclone, USA). The
BMC were centrifuged at 1000 ×g for 5 minutes and
then resuspended in medium supplemented with recom-
binant mIL-3 (200 units/ml), hIL-6 (200 units/ml) and
murine stem cell factor (mSCF, 2.5 ng/ml). Cytokines
were obtained from Peprotech (Mexico). Cells were cul-
tivated in a humidified 37°C, 5% CO2 incubator for 48-
72 hours before continuing with the transduction.
Transduction of BMC
Non-tissue culture treated 35 mm Petri dishes were
treated with Retronectin (Takara, Japan), 20 μg/cm2,
incubated with 1× phosphate buffered saline (PBS)
containing 2% FCS for 30 minutes at 37°C, removed
and then the treated plates pre-loaded with virus parti-
cles. For this, 2 × 107 virus particles were added and
allowed to incubate at 37°C for 90 minutes, removed,
and a fresh aliquot of virus was added for a second
round of pre-loading. BMC cells, 4 × 106 (in medium
plus cytokines) were then added to the dish along with
a final aliquot of virus preparation, resulting in a mul-
tiplicity of infection (MOI) of 15. Cells were main-
tained during 48 hours before proceeding with
transplantation.
Transplantation of BMC
Recipient, isogenic young adult female animals were
irradiated from a cobalt source, 8.5 Gy with attenuation
(with professional assistance from Elisabeth Somesssari,
Instituto de Pesquisas em Energia Nuclear, São Paulo).
Immediately after irradiation, animals were injected i.v.
with 4 × 106 BMC (with or without transduction, as
indicated) in 100 μl of 1× PBS. In parallel, irradiated
animals were maintained under the same conditions,
but without having received a BMC injection, in order
to serve as a control of the experimental procedure. Tet-
racycline, 100 mg/ml, was added to drinking water as a
preventative measure to avoid infections and animals
were maintained in micro-isolator cages until the con-
trols had died, usually 18-21 days, and then the trans-
plant recipients were maintained in standard cages.
Hematologic analysis of peripheral blood
Blood was collected immediately upon sacrifice by car-
diac puncture and mixed with EDTA to prevent
coagulation. Differential counts were performed manu-
ally with Panotic stained blood smears. Assays were per-
formed by the Centro de Bioterismo, FM-USP.
Isolation of genomic DNA and detection of provirus and
chimerism by Real-Time PCR
For the PCR reactions (performed in triplicate), 6.5 ng
of gDNA, 200 nM of each primer, 10 μl of 2× SYBR
Green PCR Master Mix (Applied Biosystems) and 7.4 μl
of water were used. Control reactions without template
or without primers were also performed. Amplification
was carried out using a 7500 Fast System PCR (Applied
Biosystems) under the following conditions: Stage 1, 95°
C for 10 min; Stage 2, 40 cycles of 95°C for 15 sec and
60°C for 1 min; Stage 3: 95°C for 15 sec, 60°C for 1 min,
95°C for 15 sec followed by termination at 60°C for 1
min. The primers used were: pCLeGFP Forward (5’
CCCGACAACCACTACCTGA-3’) and pCLeGFP
Reverse (5’ TCCACACCCTAACTGACACA 3’), b-Actin
Forward (5’ AGAGGGAAATCGTGCGTGAC 3’) and b-
Actin Reverse (5’ CAATAGTGATGACCTGGCCGT 3’),
Y chromosome Forward (5’ GCGCCCCATGAATGCAT
3’) and Y chromosome Reverse (5’ TCCACCTG-
CATCCCAGCT 3’) with expected amplicons of 191,
137 and 112 base-pairs, respectively. The b-Actin and Y
chromosome oligo design was derived from Mortellaro
et al [24]. The pCLeGFP oligos (which also serve for
detection of pCLPGeGFP) were designed using Primer 3
and Net Primer, then specificity was verified by BLAST.
The b-Actin control served to ensure that variations
were not due to errors in gDNA quantification and
handling.
In vivo treatment with 5-azacytidine
Animals maintained for long term observation (n = 6) in
each group were subdivided. For each group, 3 animals
were maintained as controls and the other 3 were
injected i.p. with 1 mg/kg of 5-azacytidine (Sigma) in 1×
PBS. After 24-hours, all animals were sacrificed and
BMC, peripheral blood, thymus and spleen were col-
lected for further analysis.
Additional file 1: Table showing the complete hematologic exams
(short term observation groups). Complete hematologic exams (short
term observation groups).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1743-422X-7-16-
S1.doc ]
Additional file 2: Table showing the complete hematologic exams
(long term observation groups). Complete hematologic exams (long
term observation groups).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1743-422X-7-16-
S2.doc ]
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